JP2020183439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183439A5 JP2020183439A5 JP2020127851A JP2020127851A JP2020183439A5 JP 2020183439 A5 JP2020183439 A5 JP 2020183439A5 JP 2020127851 A JP2020127851 A JP 2020127851A JP 2020127851 A JP2020127851 A JP 2020127851A JP 2020183439 A5 JP2020183439 A5 JP 2020183439A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- antibody
- composition according
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 108010028554 LDL Cholesterol Proteins 0.000 claims 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 108010023302 HDL Cholesterol Proteins 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 101150102415 Apob gene Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 101710095342 Apolipoprotein B Proteins 0.000 claims 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022108732A JP7467538B2 (ja) | 2014-07-16 | 2022-07-06 | ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025362P | 2014-07-16 | 2014-07-16 | |
| US62/025,362 | 2014-07-16 | ||
| US201462043144P | 2014-08-28 | 2014-08-28 | |
| US62/043,144 | 2014-08-28 | ||
| US201462080717P | 2014-11-17 | 2014-11-17 | |
| US62/080,717 | 2014-11-17 | ||
| EP15305419.2 | 2015-03-23 | ||
| EP15305419 | 2015-03-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502262A Division JP2017528427A (ja) | 2014-07-16 | 2015-07-16 | ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108732A Division JP7467538B2 (ja) | 2014-07-16 | 2022-07-06 | ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020183439A JP2020183439A (ja) | 2020-11-12 |
| JP2020183439A5 true JP2020183439A5 (enExample) | 2021-01-28 |
| JP7104108B2 JP7104108B2 (ja) | 2022-07-20 |
Family
ID=67107254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127851A Active JP7104108B2 (ja) | 2014-07-16 | 2020-07-29 | ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP7104108B2 (enExample) |
| ES (1) | ES2779402T3 (enExample) |
| IL (1) | IL250080B (enExample) |
| PT (1) | PT3169353T (enExample) |
| ZA (1) | ZA201700195B (enExample) |
-
2015
- 2015-07-16 ES ES15753227T patent/ES2779402T3/es active Active
- 2015-07-16 PT PT157532276T patent/PT3169353T/pt unknown
-
2017
- 2017-01-10 ZA ZA2017/00195A patent/ZA201700195B/en unknown
- 2017-01-12 IL IL250080A patent/IL250080B/en active IP Right Grant
-
2020
- 2020-07-29 JP JP2020127851A patent/JP7104108B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528427A5 (enExample) | ||
| AU2020203636B2 (en) | Use of a PCSK9 inhibitor to treat hyperlipidemia | |
| US20230406957A1 (en) | Dosing regimens for use with pcsk9 inhibitors | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| RU2016142277A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2017506626A5 (enExample) | ||
| JP2022141868A (ja) | 心血管リスクを低減させる方法 | |
| JP5806110B2 (ja) | 中和プロタンパク質コンベルターゼズブチリシンケクシン９型（ｐｃｓｋ９）変形物及びその使用 | |
| JP2016538277A5 (enExample) | ||
| JP2022177142A5 (enExample) | ||
| JP2016538248A5 (enExample) | ||
| JP2019514907A5 (enExample) | ||
| TW201306865A (zh) | 治療或預防膽固醇相關疾病之方法 | |
| CN103314011A (zh) | 胰高血糖素受体的人抗体 | |
| JP2013023499A5 (enExample) | ||
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| RU2017104799A (ru) | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию | |
| Yoshimoto et al. | Second‐generation SYK inhibitor entospletinib ameliorates fully established inflammation and bone destruction in the cherubism mouse model | |
| JP2020183439A5 (enExample) | ||
| CN105407909A (zh) | 用于治疗高血糖症的载脂蛋白a-i源性肽 | |
| JP2020519658A (ja) | 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 | |
| ES2779126T3 (es) | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia | |
| Nicholls et al. | Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia | |
| JPWO2021119321A5 (enExample) | ||
| Singh et al. | Antiatherosclerotic Agents and Cholesterol Lowering Vaccine |